|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-5-13
|
|
pubmed:abstractText |
The monoclonal antibody natalizumab is a novel therapeutic option in the treatment of relapsing forms of multiple sclerosis. In general, therapy with natalizumab is well tolerated. Allergic reactions and acute infusion reactions typically occur during or shortly after infusion, with a peak at the second infusion. Delayed infusion reactions resembling serum sickness-type reactions (type III reaction) are commonly reported in other monoclonal antibody therapies (eg, infliximab and rituximab), but are not described yet for natalizumab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1538-3687
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
656-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18474743-Adult,
pubmed-meshheading:18474743-Antibodies, Monoclonal,
pubmed-meshheading:18474743-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18474743-Autoantibodies,
pubmed-meshheading:18474743-Drug Hypersensitivity,
pubmed-meshheading:18474743-Female,
pubmed-meshheading:18474743-Humans,
pubmed-meshheading:18474743-Hypersensitivity, Delayed,
pubmed-meshheading:18474743-Immunologic Factors,
pubmed-meshheading:18474743-Infusions, Intravenous,
pubmed-meshheading:18474743-Methylprednisolone,
pubmed-meshheading:18474743-Multiple Sclerosis,
pubmed-meshheading:18474743-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Allergic and nonallergic delayed infusion reactions during natalizumab therapy.
|
|
pubmed:affiliation |
Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
